On November 20, 2019 IOTA Pharmaceuticals Ltd (Cambridge, UK) and the Experimental Therapeutic Unit of the Neurology Department of Massachusetts General Hospital (Neurology, MGH, Boston, USA) reported the creation of a new Glioblastoma drug screening pipeline, PHOENIX (Press release, IOTA Pharmaceuticals, NOV 20, 2019, View Source [SID1234551544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on IOTA’s GBM Drug Bank1 and MGH’s Glioblastoma patient-derived cell screening platforms2, PHOENIX will translate IOTA’s preclinical work on drug-induced gene expression in established GBM cell lines into a clinic-facing pipeline of effective drug combinations that could form the basis for personalised glioblastoma treatments.

The establishment of PHOENIX and the initial findings which have informed the platform will be reported at the American Society for Neuro Oncology meeting being held later this week in Phoenix, Arizona.

PHOENIX has been created with funds received from The Brain Tumour Charity (UK).

1 GBM Drug Bank-a new resource for glioblastoma drug discovery and informatics research.
2 Patient-Derived Glioma Models: From Patients to Dish to Animals.

Information on the PHOENIX pipeline, and how you can participate, can be obtained from Prof Bakhos Tannous at MGH ([email protected]) and Dr David Bailey at IOTA ([email protected]).